SG10201406070UA - Insulin receptor binding antibodies - Google Patents
Insulin receptor binding antibodiesInfo
- Publication number
- SG10201406070UA SG10201406070UA SG10201406070UA SG10201406070UA SG10201406070UA SG 10201406070U A SG10201406070U A SG 10201406070UA SG 10201406070U A SG10201406070U A SG 10201406070UA SG 10201406070U A SG10201406070U A SG 10201406070UA SG 10201406070U A SG10201406070U A SG 10201406070UA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor binding
- insulin receptor
- binding antibodies
- antibodies
- insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24606709P | 2009-09-25 | 2009-09-25 | |
| US30632110P | 2010-02-19 | 2010-02-19 | |
| US35874910P | 2010-06-25 | 2010-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201406070UA true SG10201406070UA (en) | 2014-11-27 |
Family
ID=43127165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201406070UA SG10201406070UA (en) | 2009-09-25 | 2010-09-25 | Insulin receptor binding antibodies |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8926976B2 (en) |
| EP (2) | EP2957296B1 (en) |
| JP (3) | JP5849050B2 (en) |
| KR (1) | KR101890210B1 (en) |
| CN (2) | CN102985110B (en) |
| AU (1) | AU2010298037B2 (en) |
| BR (1) | BR112012006567B1 (en) |
| CA (3) | CA3061383C (en) |
| DK (1) | DK2480254T3 (en) |
| EA (1) | EA035135B1 (en) |
| ES (2) | ES2565058T3 (en) |
| HK (1) | HK1173668A1 (en) |
| IL (2) | IL218770A (en) |
| MX (2) | MX356085B (en) |
| NZ (2) | NZ598713A (en) |
| SG (1) | SG10201406070UA (en) |
| WO (1) | WO2011038302A2 (en) |
| ZA (1) | ZA201202162B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010298036B2 (en) | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| DK3150632T3 (en) | 2011-06-10 | 2020-04-27 | Canada Minister Nat Defence | ANTI-RICIN ANTIBODIES AND APPLICATIONS THEREOF |
| EP2785376B1 (en) | 2011-11-02 | 2019-09-18 | University Of Rochester | Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| LT2809681T (en) | 2012-01-31 | 2019-02-11 | Regeneron Pharmaceuticals, Inc. | Anti-asic1 antibodies and uses thereof |
| NZ628382A (en) * | 2012-03-08 | 2017-03-31 | Janssen Vaccines & Prevention Bv | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
| US20150166654A1 (en) * | 2012-05-30 | 2015-06-18 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| CA2881966C (en) | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| EP2925351A4 (en) * | 2012-11-29 | 2016-08-24 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C (aPC) |
| WO2014105849A1 (en) * | 2012-12-28 | 2014-07-03 | Xoma (Us) Llc | Antibodies specific for fgfr4 and methods of use |
| CA2898239A1 (en) * | 2013-01-23 | 2014-07-31 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
| CN104231080B (en) * | 2013-03-15 | 2019-07-02 | 中国医学科学院药物研究所 | Human anti-human interleukin-17 A single-chain antibody |
| DK3078744T3 (en) | 2013-12-04 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | ANTIGEN BINDING MOLECULES, THE ANTIGEN BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF THE MOLECULES |
| DK3088517T3 (en) * | 2013-12-26 | 2023-12-04 | Mitsubishi Tanabe Pharma Corp | Humant anti-il-33-neutraliserende monoklonalt antistof |
| NZ764877A (en) | 2014-06-04 | 2023-12-22 | Biontech Res And Development Inc | Human monoclonal antibodies to ganglioside gd2 |
| ES2688035T3 (en) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Universal antigen receptor that expresses immune cells for addressing multiple multiple antigens, procedure for manufacturing it and using it for the treatment of cancer, infections and autoimmune diseases |
| EP3209776A1 (en) * | 2014-10-22 | 2017-08-30 | Crescendo Biologics Limited | Human vh domain scaffolds |
| EP3265491A1 (en) * | 2015-03-03 | 2018-01-10 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
| ES2820768T3 (en) | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Cancer treatment using TGF-beta and PD-1 inhibitors |
| WO2016203326A1 (en) * | 2015-06-17 | 2016-12-22 | Special Chemicals Ltd. | Shaving apparatus |
| ES2899917T3 (en) * | 2015-07-27 | 2022-03-15 | Posco | Aptamer against the insulin receptor and the pharmaceutical composition containing it |
| EP3331562A2 (en) * | 2015-08-06 | 2018-06-13 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
| AU2016339832B2 (en) * | 2015-10-13 | 2023-07-06 | Eureka Therapeutics, Inc. | Antibody agents specific for human CD19 and uses thereof |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| EP3490600A1 (en) | 2016-08-01 | 2019-06-05 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof |
| CA3038679A1 (en) | 2016-09-28 | 2018-04-05 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
| WO2018077851A1 (en) | 2016-10-24 | 2018-05-03 | Novo Nordisk A/S | Bioassay for insulin formulations |
| SG11201908543WA (en) | 2017-03-27 | 2019-10-30 | Univ Hokkaido Nat Univ Corp | Anti-pd-l1 antibody for detecting pd-l1 |
| CN108727491B (en) * | 2017-04-19 | 2021-02-09 | 广州市第八人民医院 | Monoclonal antibody ZK7C3 and application |
| WO2019006162A1 (en) * | 2017-06-28 | 2019-01-03 | Bluefin Biomedicine, Inc. | Anti-ly6h antibodies and antibody drug conjugates |
| JP6995508B2 (en) * | 2017-06-29 | 2022-01-14 | キヤノン株式会社 | Fixing device |
| CN113429479B (en) * | 2018-04-04 | 2023-03-10 | 中国科学院微生物研究所 | High-sensitivity yellow fever virus humanized monoclonal antibody and application thereof |
| CN109682963B (en) * | 2019-01-15 | 2021-09-21 | 重庆派金生物科技有限公司 | Method for analyzing binding rate of recombinant human insulin and analogues or conjugates thereof and insulin receptor |
| CN111826157A (en) | 2019-04-19 | 2020-10-27 | 日亚化学工业株式会社 | Fluoride phosphor, light-emitting device, and method for producing fluoride phosphor |
| US11771842B2 (en) * | 2019-05-09 | 2023-10-03 | Medicines360 | Syringes, syringe containers, kits and methods of use |
| CR20220221A (en) * | 2019-11-18 | 2022-07-11 | Janssen Biotech Inc | Anti-cd79 chimeric antigen receptors, car-t cells and uses thereof |
| WO2021202863A1 (en) * | 2020-04-02 | 2021-10-07 | Promab Biotechnologies, Inc. | Human ror-1 antibody and anti-ror-1-car-t cells |
| CN116964086A (en) * | 2020-05-18 | 2023-10-27 | 艾佩斯瑞生物制药公司 | anti-SARS-CoV-2 antibodies and uses thereof |
| US20230235029A1 (en) * | 2020-07-20 | 2023-07-27 | Integrated Biotherapeutics, Inc. | Broadly neutralizing binding molecules against marburgviruses |
| WO2022178557A2 (en) * | 2021-02-22 | 2022-08-25 | Pandion Operations, Inc. | Pancreas targeted therapeutics and uses thereof |
| CN113186275A (en) * | 2021-06-16 | 2021-07-30 | 上海交通大学医学院附属仁济医院 | Application of serum amyloid A1 in preparation of biomarker for diagnosing polycystic ovarian syndrome |
| WO2023177974A2 (en) * | 2022-03-15 | 2023-09-21 | Phanes Therapeutics, Inc. | Anti-mesothelin antibodies and uses thereof |
| WO2023225657A2 (en) * | 2022-05-20 | 2023-11-23 | Rezolute, Inc. | Formulations for anti-insulin receptor antibody and uses thereof |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JPS5896026A (en) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | Novel urokinase derivative, its preparation and thrombolytic agent containing the same |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| EP0138854B1 (en) * | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4761371A (en) * | 1985-02-12 | 1988-08-02 | Genentech, Inc. | Insulin receptor |
| CH0229046H1 (en) * | 1985-03-30 | 1998-07-15 | Stuart Alan Kauffman | METHOD FOR OBTAINING DNA, RNA, PEPTIDES, POLYPEPTINIQUE. DES OR PROTEINS BY MEANS OF A DNA RECOMBINANT TECH |
| NZ215865A (en) * | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5763192A (en) * | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| DE3889853D1 (en) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharide-modified immunoglobulins with reduced immunogenic potential or improved pharmacokinetics. |
| US5266684A (en) * | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) * | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP0494955B1 (en) * | 1989-10-05 | 1998-07-15 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (en) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | GENERATION OF XENOGENE ANTIBODIES |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5770434A (en) * | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0558671B1 (en) * | 1990-11-21 | 1999-01-27 | Iterex Pharmaceuticals Ltd. Partnership | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
| US5164295A (en) * | 1991-03-06 | 1992-11-17 | The Upjohn Company | Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds |
| DK1471142T3 (en) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
| DE69233254T2 (en) * | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
| DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5348867A (en) * | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
| PT1696031E (en) | 1991-12-02 | 2010-06-25 | Medical Res Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| DE69233204T2 (en) * | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE |
| FI92507C (en) | 1991-12-19 | 1994-11-25 | Valto Ilomaeki | Method and apparatus for controlling pipes laid in the ground |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| DE69333115D1 (en) * | 1992-09-22 | 2003-08-28 | Biofocus Discovery Ltd | RECOMBINANT VIRUSES PRESENTING A NON-VIRAL POLYPEPTIDE ON THEIR OUTER SURFACE |
| US5610031A (en) * | 1993-10-27 | 1997-03-11 | The General Hospital Corporation | B1k chain of laminin and methods of use |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| US6054287A (en) * | 1994-05-27 | 2000-04-25 | Methodist Hospital Of Indiana, Inc. | Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species |
| EP0692539B1 (en) | 1994-07-11 | 1999-09-22 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing an optically active gamma-hydroxy-L-glutamic acid |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
| US6489145B1 (en) | 1996-07-09 | 2002-12-03 | Diversa Corporation | Method of DNA shuffling |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
| US6699658B1 (en) * | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US5766905A (en) * | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
| GB9712818D0 (en) * | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6028169A (en) * | 1997-03-31 | 2000-02-22 | Human Genome Sciences, Inc. | Chemokine β-6 antagonists |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6303373B1 (en) | 1999-06-09 | 2001-10-16 | Whitehead Institute For Biomedical Research | Method of measuring plasma membrane targeting of GLUT4 |
| US20030044772A1 (en) * | 1997-08-04 | 2003-03-06 | Applied Molecular Evolution [Formerly Ixsys] | Methods for identifying ligand specific binding molecules |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2003099199A2 (en) | 1999-05-19 | 2003-12-04 | Duke University | Compositions and methods for promoting or inhibiting angiogenesis |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| GB0014838D0 (en) | 2000-06-16 | 2000-08-09 | Univ Bristol | An assay |
| US6342358B1 (en) * | 2000-08-24 | 2002-01-29 | The Regents Of The University Of California | Human telomerase RNA elements |
| EP1916303B1 (en) | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7208279B2 (en) | 2001-03-14 | 2007-04-24 | Caden Biosciences, Inc. | Method for identifying inhibitors of G protein coupled receptor signaling |
| JP2004532038A (en) | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | Application of novel antigen-binding molecules to therapeutic, diagnostic, prophylactic, enzymatic, industrial and agricultural fields, and methods for producing and screening novel antigen-binding molecules therefor |
| WO2002094194A2 (en) | 2001-05-22 | 2002-11-28 | Duke University | Compositions and methods for inhibiting metastasis |
| WO2003008930A2 (en) | 2001-07-16 | 2003-01-30 | Icos Corporation | Lfa-1 binding agents that recognize neoepitopes |
| JP4213586B2 (en) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | Camel antibody library production method |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003083057A2 (en) * | 2002-03-22 | 2003-10-09 | Joslin Diabetes Center, Inc. | Adipocytes and uses thereof |
| MXPA04009418A (en) | 2002-03-29 | 2005-06-08 | Schering Corp | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same. |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| CA2519361A1 (en) | 2003-03-21 | 2004-10-07 | Schering Corporation | Method of screening for target ligands |
| WO2004097414A1 (en) * | 2003-04-25 | 2004-11-11 | Medical And Biological Laboratories Co., Ltd. | METHOD OF MEASURING INSULIN RECEPTOR α SUBUNIT |
| AU2003904237A0 (en) | 2003-08-08 | 2003-08-21 | Garvan Institute Of Medical Research | Novel translocation assay |
| WO2005118635A2 (en) * | 2004-06-03 | 2005-12-15 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| US9029097B2 (en) | 2005-02-16 | 2015-05-12 | Universite De Montreal | Biosensors for monitoring receptor-mediated G-protein activation |
| US7871770B2 (en) | 2005-08-09 | 2011-01-18 | Maxwell Sensors, Inc. | Light transmitted assay beads |
| WO2007028126A2 (en) * | 2005-08-31 | 2007-03-08 | Ohio University | Methods and systems for identifying insulin mimetics |
| CA2646406A1 (en) * | 2006-03-28 | 2007-11-08 | Biogen Idec Ma Inc. | Anti-igf-ir antibodies and uses thereof |
| AU2007261782A1 (en) | 2006-06-06 | 2007-12-27 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| AU2007262666B2 (en) | 2006-06-22 | 2013-09-12 | Walter And Eliza Hall Institute Of Medical Research | Structure of the insulin receptor ectodomain |
| US20090258020A1 (en) | 2008-01-07 | 2009-10-15 | Patrys Limited | Antibody designated barb3, barb3 related antibodies, and methods of making and using same |
| EP2341936A4 (en) | 2008-09-05 | 2012-07-25 | Xoma Technology Ltd | METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES |
| US9101117B2 (en) | 2009-06-10 | 2015-08-11 | Aarhus Universitet | SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| AU2010298036B2 (en) | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
-
2010
- 2010-09-24 US US12/890,598 patent/US8926976B2/en active Active
- 2010-09-25 SG SG10201406070UA patent/SG10201406070UA/en unknown
- 2010-09-25 EP EP15174585.8A patent/EP2957296B1/en active Active
- 2010-09-25 EA EA201270465A patent/EA035135B1/en not_active IP Right Cessation
- 2010-09-25 ES ES10766418.7T patent/ES2565058T3/en active Active
- 2010-09-25 BR BR112012006567-0A patent/BR112012006567B1/en active IP Right Grant
- 2010-09-25 CN CN201080053159.XA patent/CN102985110B/en active Active
- 2010-09-25 WO PCT/US2010/050313 patent/WO2011038302A2/en active Application Filing
- 2010-09-25 MX MX2015008398A patent/MX356085B/en unknown
- 2010-09-25 AU AU2010298037A patent/AU2010298037B2/en active Active
- 2010-09-25 KR KR1020127010579A patent/KR101890210B1/en active IP Right Grant
- 2010-09-25 ES ES15174585T patent/ES2733629T3/en active Active
- 2010-09-25 NZ NZ598713A patent/NZ598713A/en unknown
- 2010-09-25 JP JP2012531088A patent/JP5849050B2/en active Active
- 2010-09-25 NZ NZ625360A patent/NZ625360A/en unknown
- 2010-09-25 MX MX2012003521A patent/MX2012003521A/en active IP Right Grant
- 2010-09-25 CN CN201610463245.7A patent/CN106084050B/en active Active
- 2010-09-25 CA CA3061383A patent/CA3061383C/en active Active
- 2010-09-25 CA CA3061719A patent/CA3061719A1/en active Pending
- 2010-09-25 EP EP10766418.7A patent/EP2480254B1/en active Active
- 2010-09-25 DK DK10766418.7T patent/DK2480254T3/en active
- 2010-09-25 CA CA2773099A patent/CA2773099C/en active Active
-
2012
- 2012-03-21 IL IL218770A patent/IL218770A/en active IP Right Grant
- 2012-03-23 ZA ZA2012/02162A patent/ZA201202162B/en unknown
-
2013
- 2013-01-18 HK HK13100862.0A patent/HK1173668A1/en unknown
-
2014
- 2014-11-26 US US14/555,233 patent/US9944698B2/en active Active
- 2014-11-26 US US14/555,243 patent/US9725510B2/en active Active
-
2015
- 2015-11-30 JP JP2015232701A patent/JP6309940B2/en active Active
-
2016
- 2016-06-02 IL IL245984A patent/IL245984A0/en unknown
-
2017
- 2017-11-06 JP JP2017213797A patent/JP2018058854A/en active Pending
-
2018
- 2018-03-14 US US15/921,176 patent/US11261247B2/en active Active
-
2022
- 2022-01-13 US US17/575,577 patent/US20220227857A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1173668A1 (en) | Insulin receptor binding antibodies | |
| HRP20191341T8 (en) | Human cgrp receptor binding antibodies | |
| AP3371A (en) | Anti-IGF antibodies | |
| IL214996A0 (en) | Anti-bcma antibodies | |
| GB0920127D0 (en) | Antibodies | |
| GB0909906D0 (en) | Antibodies | |
| EP2427496A4 (en) | Anti-vegf-d antibodies | |
| GB0821100D0 (en) | Antibodies | |
| EP2337798A4 (en) | Bsa-specific antibodies | |
| ZA201006099B (en) | Anti-tyrp1 antibodies | |
| GB0920324D0 (en) | Antibodies | |
| PL2483309T3 (en) | Antibodies specifically binding to the epidermal growth factor receptor | |
| HK1170745A1 (en) | Antibodies against il-17br il-17br | |
| ZA201007976B (en) | Anti-pirb antibodies | |
| GB0818356D0 (en) | Antibodies | |
| EP2499256A4 (en) | Anti-c-mpl antibodies | |
| EP2424892A4 (en) | Dc-stamp antibodies | |
| GB0908945D0 (en) | Antibodies | |
| GB0823562D0 (en) | Antibodies | |
| GB0806230D0 (en) | Antibodies |